Zydus Lifesciences gets USFDA nod for Prucalopride tablets, 1 mg and 2 mg
Prucalopride works by stimulating natural peristalsis in the colon, thereby aiding regular bowel movements. With this approval, Zydus adds another feather to its cap in the US generics market. The approved tablets will be manufactured at the company's SEZ facility in Ahmedabad, Gujarat.
According to IQVIA MAT data for June 2025, Prucalopride tablets had annual sales of USD 186.8 million in the US market. This approval strengthens Zydus' position in the gastrointestinal segment and adds to its growing US portfolio.
With this latest nod, the group has now received 422 approvals since it began filing ANDAs (Abbreviated New Drug Applications) in FY 2003-04. In total, Zydus has filed 483 ANDAs so far.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 minutes ago
- Business Upturn
Marine Electricals bags Rs. 19.35 crore order from STT Global Data Centres
By Aman Shukla Published on August 11, 2025, 11:14 IST Marine Electricals (India) Limited has secured a significant new order worth Rs. 19.35 crores (excluding taxes) from STT Global Data Centres India Private Limited. The order involves the supply, installation, testing, and commissioning of a power distribution system for STT's Pune DC05 and Noida DC02 data center projects. The delivery timeline for this order is planned over the next 6 to 8 months. Importantly, the company has clarified that none of the promoters or promoter group members have any interest in this contract, confirming that it does not qualify as a related party transaction. This update has been shared in the spirit of transparent and responsible corporate governance. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
8 minutes ago
- Business Upturn
Lupin launches Glucagon for Injection in the U.S. market
By Aditya Bhagchandani Published on August 11, 2025, 10:30 IST Global pharmaceutical major Lupin Limited has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, in the United States. The product is bioequivalent to Eli Lilly's Glucagon for Injection, 1mg/vial. Glucagon is indicated for treating severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adults. According to IQVIA MAT June 2025 data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit recorded estimated annual U.S. sales of USD 122 million. Lupin, headquartered in Mumbai, operates in over 100 markets with a strong presence in India and the U.S. across multiple therapy areas. The company runs 15 manufacturing sites and seven research centers globally, supported by over 23,000 employees. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
9 minutes ago
- Business Upturn
DOMS Industries shares jump 7% as Q1 revenue rises 26.4% YoY to Rs 562 crore
By Aman Shukla Published on August 11, 2025, 10:29 IST DOMS Industries saw its shares rise 7% following robust first-quarter results. As of 10:26 AM, the shares were trading 6.82% higher at Rs 2,443.70. The company reported a 10.5% year-on-year increase in net profit to ₹57.3 crore, driven by strong revenue growth. For the quarter, DOMS Industries posted a 26.4% surge in revenue, reaching ₹562 crore. EBITDA also improved by 13.8% to ₹98.3 crore, reflecting solid operational performance. However, the EBITDA margin narrowed to 17.5% compared to 19.4% in the same period last year, indicating some pressure on profitability. In a key shareholder update, the company has set Monday, September 15, 2025, as the record date to identify eligible shareholders for the final dividend of ₹3.15 per share (face value ₹10) for the fiscal year 2024-25. This dividend was recommended in May during the company's annual results and awaits approval at the upcoming Annual General Meeting. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
